Holen Sie sich die Stockscreener-App
76.31
3.19%
2.49
Schlusskurs vom Vortag:
$73.82
Offen:
$74.48
24-Stunden-Volumen:
539.84K
Relative Volume:
0.24
Marktkapitalisierung:
$14.70B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-31.66
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
-2.63%
1M Leistung:
+6.29%
6M Leistung:
+65.67%
1J Leistung:
+158.66%
1-Tages-Spanne:
$74.46
$77.62
1-Wochen-Bereich:
$71.19
$78.58
52-Wochen-Spanne:
$28.10
$78.58
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
76.27 | 14.23B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Can BridgeBio Pharma Inc. stock hit record highs againJuly 2025 Big Picture & Daily Technical Stock Forecast Reports - ulpravda.ru
Why BridgeBio Pharma Inc. stock could rally in 2025Quarterly Market Summary & High Yield Stock Recommendations - ulpravda.ru
How BridgeBio Pharma Inc. stock compares to industry benchmarksQuarterly Profit Review & Free Long-Term Investment Growth Plans - ulpravda.ru
Is BridgeBio Pharma Inc. stock a bargain at current levels2025 Risk Factors & Weekly High Return Forecasts - ulpravda.ru
How BridgeBio Pharma Inc. stock reacts to oil prices2025 Pullback Review & Fast Entry Momentum Trade Alerts - ulpravda.ru
BBIO: Truist Securities Raises Price Target to $86, Maintains Bu - GuruFocus
Will BridgeBio Pharma Inc. stock benefit from green energy trendsCPI Data & Fast Entry Momentum Trade Alerts - ulpravda.ru
Intratumoral Cancer Therapies Market Expected to Reach US$ - openPR.com
Is BridgeBio Pharma (BBIO) Pricing Reflect Long Term Potential After 156.5% One Year Surge - Yahoo Finance
BBIO's Analyst Rating: Morgan Stanley Initiates Coverage with Ov - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Morgan Stanley - MarketBeat
BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says - MarketScreener
Morgan Stanley Initiates BridgeBio Pharma at Overweight With $96 Price Target - marketscreener.com
Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating By Investing.com - Investing.com Canada
Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating - Investing.com India
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 6.5%Should You Sell? - MarketBeat
BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms - TechStock²
BridgeBio to Participate in the J.P. Morgan Healthcare Conference - The Manila Times
BridgeBio Pharma stock hits all-time high at 78.46 USD By Investing.com - Investing.com Nigeria
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month HighHere's What Happened - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.46 USD - Investing.com
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET - The Manila Times
BridgeBio Pharma to Host Investor Webinar on Infigratinib and Achondroplasia Treatment Developments - Quiver Quantitative
Moody Aldrich Partners LLC Has $3.72 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc.Common Stock (NQ: BBIO - FinancialContent
BridgeBio Pharma Earnings Notes - Trefis
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Behavioral Patterns of BBIO and Institutional Flows - Stock Traders Daily
Corient Private Wealth LLC Acquires New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Aug Chart Watch: How BridgeBio Pharma Inc stock compares to industry benchmarksWeekly Trend Summary & Precise Trade Entry Recommendations - moha.gov.vn
BridgeBio Has More Room To Run (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma stock hits all-time high at $77.32 By Investing.com - Investing.com Nigeria
BridgeBio Pharma stock hits all-time high at $77.32 - Investing.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assenagon Asset Management S.A. Trims Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Why global investors buy BridgeBio Pharma Inc. (2CL) stockJuly 2025 Fed Impact & Low Risk Entry Point Guides - Улправда
Will BridgeBio Pharma Inc. stock benefit from commodity pricesTrade Entry Report & Real-Time Sentiment Analysis - Улправда
First Week of August 2026 Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
What hedge fund activity signals for BridgeBio Pharma Inc. stock2025 Big Picture & Reliable Entry Point Trade Alerts - Улправда
Gains Recap: Why BridgeBio Pharma Inc. stock could rally in 2025Analyst Upgrade & Weekly Top Stock Performers List - Улправда
Will BridgeBio Pharma Inc. stock maintain growth story2025 Market Trends & Low Risk Growth Stock Ideas - Улправда
BridgeBio Pharma Sees Unusually Large Options Volume (NASDAQ:BBIO) - MarketBeat
Layoff Watch: What hedge fund activity signals for BridgeBio Pharma Inc. stockJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Path To Profitability - 富途牛牛
Hypoparathyroidism Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 30,011 Shares - MarketBeat
Pres Trimarchi Acquires 11,174 Of Bridgebio Pharma Inc [BBIO] - TradingView — Track All Markets
BridgeBio Pharma (BBIO) CEO discloses RSU vesting and stock sales - Stock Titan
Officer Apuli Acquires 1,941 Of Bridgebio Pharma Inc [BBIO] - TradingView — Track All Markets
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):